VDR rs7975232 / ApaI遗传变异预测用聚乙二醇化干扰素治疗的HBeAg

StephenW

J Med Virol. 2018 Dec 5. doi: 10.1002/jmv.25373. [Epub ahead of print]
VDR rs7975232/ApaI genetic variation predicts sustained HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with pegylated interferon.
Ben S1,2, Yan WJ1, Xia W1, Juan FJ1, Li L1, Cheng PX1, Jun LJ3, Tuan TX4.
Author information

1
    The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
2
    The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
3
    The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
4
    The Affiliated Pizhou Hospital of Xuzhou Medical University, Xuzhou, China.

Abstract
AIM:

To evaluate the predictive value of vitamin D and its metabolic pathway gene polymorphisms in response to pegylated interferon (Peg-IFN) in HBeAg-positive CHB patients.
METHODS:

119 HBeAg-positive CHB patients who received Peg-IFN monotherapy for 48 weeks and then were followed-up for another 48 weeks were prospectively enrolled; baseline 25-(OH)D and HBV serologic marker levels were detected, 9 critical single nucleotide polymorphisms within vitamin D metabolism were genotyped.
RESULTS:

45 (37.8%), 44 (37.0%), 35 (29.4%) and 11 (9.2%) of the patients achieved VR, HBeAg loss, CR and HBsAg level <200 IU/ml at the end of treatment (EOT; week 48), respectively; 42 (35.3%) and 6 (5.0%) people achieved HBeAg and HBsAg loss at the end of follow-up (EOF; week 96). Baseline HBeAg level was independent predictor of VR (OR=0.470, 95% CI: 0.294-0.751, P=0.002), HBeAg loss (OR=0.395, 95% CI: 0.243-0.643, P<0.001), CR (OR=0.392, 95% CI: 0.215-0.714, P=0.002) at EOT and HBeAg loss at EOF (OR=0.334, 95% CI: 0.203-0.559, P<0.001); baseline HBsAg level itself was independent predictor of both HBsAg<200 IU/ml at EOT (OR=0.257, 95% CI: 0.103-0.642, P=0.004) and HBsAg loss at EOF (OR=0.232, 95% CI: 0.077-0.702, P=0.010). Age was also independent predictors of HBsAg loss at EOF (OR=0.775, 95% CI: 0.634-0.948, P=0.013). Concerning genetic variation of VDR rs7975232/ApaI, A allele was the genetic independent predictor of VR at EOT (OR=1.824, 95% CI: 1.024-3.248, P=0.041) and HBsAg loss at EOF (OR=3.566, 95% CI: 1.057-12.029, P=0.040).
CONCLUSIONS:

Genetic variation of VDR rs7975232/ApaI is a pretreatment predictor of sustained HBsAg loss in HBeAg-positive CHB patients with Peg-IFN monotherapy. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.
KEYWORDS:

Chronic hepatitis B; Interferon; Polymorphism; Vitamin D

PMID:
    30516836
DOI:
    10.1002/jmv.25373

StephenW

J Med Virol。 2018年12月5日doi：10.1002 / jmv.25373。 [提前打印]
VDR rs7975232 / ApaI遗传变异预测用聚乙二醇化干扰素治疗的HBeAg阳性慢性乙型肝炎患者持续HBsAg消失。
Ben S1,2，Yan WJ1，Xia W1，Juan FJ1，Li L1，Cheng PX1，Jun LJ3，Tuan TX4。
作者信息

1
    徐州医科大学附属医院，徐州，中国。
2
    徐州医科大学附属淮安医院，淮安
3
    徐州医科大学附属第二医院，徐州，中国。
4
    徐州医科大学附属P州医院，徐州，中国。

抽象
目标：

评估维生素D及其代谢途径基因多态性对HBeAg阳性CHB患者对聚乙二醇化干扰素（Peg-IFN）的反应的预测价值。
方法：

119例HBeAg阳性的CHB患者接受Peg-IFN单药治疗48周，然后进行随访48周，前瞻性研究;检测基线25-（OH）D和HBV血清学标志物水平，对维生素D代谢中的9个关键单核苷酸多态性进行基因分型。
结果：

45例（37.8％），44例（37.0％），35例（29.4％）和11例（9.2％）患者在治疗结束时达到VR，HBeAg消失，CR和HBsAg水平<200 IU / ml（EOT;周） 48），分别; 42例（35.3％）和6例（5.0％）患者在随访结束时（EOF;第96周）出现HBeAg和HBsAg消失。基线HBeAg水平是VR的独立预测因子（OR = 0.470,95％CI：0.294-0.751，P = 0.002），HBeAg消失（OR = 0.395,95％CI：0.243-0.643，P <0.001），CR（OR =在EOT时0.392,95％CI：0.215-0.714，P = 0.002）和在EOF时HBeAg损失（OR = 0.334,95％CI：0.203-0.559，P <0.001）;基线HBsAg水平本身是EOT时HBsAg <200 IU / ml的独立预测因子（OR = 0.257,95％CI：0.103-0.642，P = 0.004）和EOF时HBsAg消失（OR = 0.232,95％CI：0.077- 0.702，P = 0.010）。年龄也是EOF时HBsAg消失的独立预测因子（OR = 0.775,95％CI：0.634-0.948，P = 0.013）。关于VDR rs7975232 / ApaI的遗传变异，A等位基因是EOT VR的遗传独立预测因子（OR = 1.824,95％CI：1.024-3.248，P = 0.041）和EOF时HBsAg丢失（OR = 3.566,95％CI） ：1.057-12.029，P = 0.040）。
结论：

VDR的遗传变异rs7975232 / ApaI是用Peg-IFN单药治疗HBeAg阳性CHB患者持续HBsAg消失的预处理预测因子。本文受版权保护。版权所有。

本文受版权保护。版权所有。
关键词：

慢性乙型肝炎;干扰素;多态性;维生素D

结论：
    30516836
DOI：
    10.1002 / jmv.25373

齐欢畅